Cargando…
Safety and pharmacokinetics of dicloxacillin in healthy Chinese volunteers following single and multiple oral doses
BACKGROUND: Dicloxacillin, a semisynthetic isoxazolyl penicillin antibiotic, has antimicrobial activity against a wide variety of gram-positive bacteria including Staphylococcus aureus, Streptococcus pyogenes, Streptococcus pneumonia, Streptococcus epidermidis, Streptococcus viridans, Streptococcus...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4621192/ https://www.ncbi.nlm.nih.gov/pubmed/26527863 http://dx.doi.org/10.2147/DDDT.S92117 |
_version_ | 1782397399728128000 |
---|---|
author | Wu, Guolan Zheng, Yunliang Zhou, Huili Hu, Xingjiang Liu, Jian Zhai, You Zhu, Meixiang Wu, Lihua Shentu, Jianzhong |
author_facet | Wu, Guolan Zheng, Yunliang Zhou, Huili Hu, Xingjiang Liu, Jian Zhai, You Zhu, Meixiang Wu, Lihua Shentu, Jianzhong |
author_sort | Wu, Guolan |
collection | PubMed |
description | BACKGROUND: Dicloxacillin, a semisynthetic isoxazolyl penicillin antibiotic, has antimicrobial activity against a wide variety of gram-positive bacteria including Staphylococcus aureus, Streptococcus pyogenes, Streptococcus pneumonia, Streptococcus epidermidis, Streptococcus viridans, Streptococcus agalactiae, and Neisseria meningitidis. The objective of this study was to evaluate the safety and pharmacokinetic profile of dicloxacillin after single and multiple oral dose in healthy Chinese volunteers. METHODS: A single-center, open-label, randomized, two-phase study was conducted in 16 subjects. In the single-dose phase, subjects were randomly assigned to receive single doses of 0.25, 0.5, 1.0, and 2.0 g of dicloxacillin sodium capsule in a 4-way crossover design with a 5-day washout period between administrations. In the multiple-dose phase, subjects were assigned to receive 0.25 or 0.5 g every 6 hours for 3 days in a 2-way crossover design. Plasma and urine pharmacokinetic samples were assayed by a validated high-performance liquid chromatography-tandem mass spectrometry method. Pharmacokinetic parameters were calculated and analyzed statistically. Safety assessments were conducted throughout the study. RESULTS: Following a single oral dose of 0.25–2.0 g dicloxacillin sodium, the maximum plasma drug concentration (C(max)) and the corresponding values for the area under the concentration– time curve from 0 to 10 hours (AUC0–10 h) increased in a dose-proportional manner. The mean elimination half-life (t(1/2)) was in the range of 1.38–1.71 hours. Dicloxacillin was excreted in its unchanged form via the kidney, with no tendency of accumulation, and varied from 38.65% to 50.10%. No appreciable accumulation of drug occurred with multiple oral doses of dicloxacillin. No serious adverse events were reported. Adverse events were generally mild. CONCLUSION: Dicloxacillin was safe and well tolerated in the volunteers and displayed linear increases in the C(max) and AUC(0–10 h) values. |
format | Online Article Text |
id | pubmed-4621192 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-46211922015-11-02 Safety and pharmacokinetics of dicloxacillin in healthy Chinese volunteers following single and multiple oral doses Wu, Guolan Zheng, Yunliang Zhou, Huili Hu, Xingjiang Liu, Jian Zhai, You Zhu, Meixiang Wu, Lihua Shentu, Jianzhong Drug Des Devel Ther Original Research BACKGROUND: Dicloxacillin, a semisynthetic isoxazolyl penicillin antibiotic, has antimicrobial activity against a wide variety of gram-positive bacteria including Staphylococcus aureus, Streptococcus pyogenes, Streptococcus pneumonia, Streptococcus epidermidis, Streptococcus viridans, Streptococcus agalactiae, and Neisseria meningitidis. The objective of this study was to evaluate the safety and pharmacokinetic profile of dicloxacillin after single and multiple oral dose in healthy Chinese volunteers. METHODS: A single-center, open-label, randomized, two-phase study was conducted in 16 subjects. In the single-dose phase, subjects were randomly assigned to receive single doses of 0.25, 0.5, 1.0, and 2.0 g of dicloxacillin sodium capsule in a 4-way crossover design with a 5-day washout period between administrations. In the multiple-dose phase, subjects were assigned to receive 0.25 or 0.5 g every 6 hours for 3 days in a 2-way crossover design. Plasma and urine pharmacokinetic samples were assayed by a validated high-performance liquid chromatography-tandem mass spectrometry method. Pharmacokinetic parameters were calculated and analyzed statistically. Safety assessments were conducted throughout the study. RESULTS: Following a single oral dose of 0.25–2.0 g dicloxacillin sodium, the maximum plasma drug concentration (C(max)) and the corresponding values for the area under the concentration– time curve from 0 to 10 hours (AUC0–10 h) increased in a dose-proportional manner. The mean elimination half-life (t(1/2)) was in the range of 1.38–1.71 hours. Dicloxacillin was excreted in its unchanged form via the kidney, with no tendency of accumulation, and varied from 38.65% to 50.10%. No appreciable accumulation of drug occurred with multiple oral doses of dicloxacillin. No serious adverse events were reported. Adverse events were generally mild. CONCLUSION: Dicloxacillin was safe and well tolerated in the volunteers and displayed linear increases in the C(max) and AUC(0–10 h) values. Dove Medical Press 2015-10-16 /pmc/articles/PMC4621192/ /pubmed/26527863 http://dx.doi.org/10.2147/DDDT.S92117 Text en © 2015 Wu et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Wu, Guolan Zheng, Yunliang Zhou, Huili Hu, Xingjiang Liu, Jian Zhai, You Zhu, Meixiang Wu, Lihua Shentu, Jianzhong Safety and pharmacokinetics of dicloxacillin in healthy Chinese volunteers following single and multiple oral doses |
title | Safety and pharmacokinetics of dicloxacillin in healthy Chinese volunteers following single and multiple oral doses |
title_full | Safety and pharmacokinetics of dicloxacillin in healthy Chinese volunteers following single and multiple oral doses |
title_fullStr | Safety and pharmacokinetics of dicloxacillin in healthy Chinese volunteers following single and multiple oral doses |
title_full_unstemmed | Safety and pharmacokinetics of dicloxacillin in healthy Chinese volunteers following single and multiple oral doses |
title_short | Safety and pharmacokinetics of dicloxacillin in healthy Chinese volunteers following single and multiple oral doses |
title_sort | safety and pharmacokinetics of dicloxacillin in healthy chinese volunteers following single and multiple oral doses |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4621192/ https://www.ncbi.nlm.nih.gov/pubmed/26527863 http://dx.doi.org/10.2147/DDDT.S92117 |
work_keys_str_mv | AT wuguolan safetyandpharmacokineticsofdicloxacillininhealthychinesevolunteersfollowingsingleandmultipleoraldoses AT zhengyunliang safetyandpharmacokineticsofdicloxacillininhealthychinesevolunteersfollowingsingleandmultipleoraldoses AT zhouhuili safetyandpharmacokineticsofdicloxacillininhealthychinesevolunteersfollowingsingleandmultipleoraldoses AT huxingjiang safetyandpharmacokineticsofdicloxacillininhealthychinesevolunteersfollowingsingleandmultipleoraldoses AT liujian safetyandpharmacokineticsofdicloxacillininhealthychinesevolunteersfollowingsingleandmultipleoraldoses AT zhaiyou safetyandpharmacokineticsofdicloxacillininhealthychinesevolunteersfollowingsingleandmultipleoraldoses AT zhumeixiang safetyandpharmacokineticsofdicloxacillininhealthychinesevolunteersfollowingsingleandmultipleoraldoses AT wulihua safetyandpharmacokineticsofdicloxacillininhealthychinesevolunteersfollowingsingleandmultipleoraldoses AT shentujianzhong safetyandpharmacokineticsofdicloxacillininhealthychinesevolunteersfollowingsingleandmultipleoraldoses |